查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595213

帕金森氏症药物市场：按类型、药物类别、分销管道、最终用途分类 - 全球预测 2025-2030

Parkinson's Disease Therapeutics Market by Type (Intestinal Infusion, Oral, Subcutaneous), Drug Class (Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor), Distribution Channel, End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年帕金森氏症药物市场价值为66.7亿美元，预计到2024年将达到72.1亿美元，复合年增长率为8.28%，预计到2030年将达到116.4亿美元。

帕金森氏症药物包括旨在控制帕金森氏症患者症状和改善生活品质的治疗方法。这个市场包括药物疗法、手术疗法以及新型基因和细胞疗法。帕金森氏症是第二常见的神经退化性疾病，随着人口老化，患者数量不断增加，这一事实推动了对这些治疗的需求。治疗方法包括左旋多巴和多巴胺促效剂等药物到深部脑部刺激等手术介入。最终使用领域包括满足患者需求和测试新疗法的医院、诊所和研究机构。影响市场成长的主要因素包括药物发现和药物输送系统的技术进步、研发活动的活性化以及医疗支出的增加。此外，策略联盟和个人化医疗的快速成长也代表着重大商机。公司可以透过利用研发伙伴关係关係并专注于奈米技术等创新交付平台来抓住这些机会。然而，市场扩张面临高昂的治疗成本、严格的监管要求以及长期药物潜在副作用的挑战。我们对帕金森氏症发病机制的了解有限，这使得研究和开发工作更加复杂。识别早期诊断的生物标记、开发非侵入性治疗方法以及提高药物疗效和安全性等创新领域的探索时机已经成熟。公司应该投资深度学习和人工智慧技术，以加速药物发现和针对患者的治疗计划。儘管存在这些挑战，但在对改进治疗方法的持续需求和鼓励突破的支持性法规环境的推动下，市场本质上是动态的。策略规划涉及将稳健的研发计划与适应性监管策略相结合，以应对复杂的情况并确保这一重要医疗保健行业的永续成长。

主要市场统计
基准年[2023] 66.7亿美元
预测年份 [2024] 72.1亿美元
预测年份 [2030] 116.4亿美元
复合年增长率（%） 8.28%

市场动态：揭示快速发展的帕金森氏症药物市场的关键市场洞察

供需的动态交互作用正在改变帕金森氏症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 高龄化社会帕金森氏症患者病率增加
    • 开发新的治疗方法和新的微创设备
    • 强大的临床研究药物管线
  • 市场限制因素
    • 替代治疗的可用性
  • 市场机会
    • 政府研发步伐加快
    • 专利到期为製药公司带来的可能性
  • 市场挑战
    • 帕金森氏症药物的副作用

波特五力战略工具驾驭帕金森氏症药物市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解帕金森氏症药物市场的外部影响

外部宏观环境因素在塑造帕金森氏症药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解帕金森氏症治疗药物市场的竞争状况

帕金森氏症药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 帕金森氏症药物市场定位矩阵供应商绩效评估

FPNV定位矩阵是评估帕金森氏症治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划帕金森氏症药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，帕金森氏症药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老化社会帕金森氏症发生率增加
      • 开发新的治疗方法和新的微创设备
      • 强大的药物管线正在临床研究中
    • 抑制因素
      • 替代治疗方法的可用性
    • 机会
      • 加速政府研究和开发
      • 专利到期为製药公司带来的可能性
    • 任务
      • 帕金森氏症药物副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章帕金森氏症药物市场：依类型

  • 肠内注射
  • 口服
  • 皮下的
  • 经皮的

第七章依药物类别分類的帕金森氏症药物市场

  • 抗胆碱能药
  • 碳度巴/左旋多巴
  • COMT抑制剂
  • 多巴胺受体促效剂
  • MAO抑制剂

第八章帕金森氏症药物市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第九章帕金森氏症药物市场：依最终用途

  • 诊所
  • 医院

第十章 美洲帕金森氏症药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区帕金森氏症药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲帕金森氏症药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie, Inc.
  • Acadia Pharmaceuticals Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • H. Lundbeck A/S
  • Mylan Inc. by Viatris Inc.
  • Novartis AG
  • Orion Corporation
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceuticals Industries Ltd.
  • UCB SA
  • Wockhardt Limited
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market was valued at USD 6.67 billion in 2023, expected to reach USD 7.21 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 11.64 billion by 2030.

Parkinson's Disease Therapeutics involves treatments aimed at managing symptoms and improving the quality of life for Parkinson's disease patients. This market encompasses medications, surgeries, and emerging gene and cell therapy approaches. The necessity of these therapies arises from Parkinson's being the second most common neurodegenerative disorder, with a growing patient population due to aging demographics. The application of therapies ranges from pharmaceutical drugs like levodopa and dopamine agonists to surgical interventions such as deep brain stimulation. End-use segments include hospitals, clinics, and research institutes that cater to patient needs and experiment with newer treatments. Key factors influencing market growth include technological advancements in drug discovery and delivery systems, rising R&D activities, and increased healthcare expenditures. Additionally, strategic collaborations and the burgeoning field of personalized medicine present substantial opportunities. Companies can seize these by leveraging partnerships for R&D and focusing on innovative delivery platforms like nanotechnology. However, market expansion is challenged by high treatment costs, stringent regulatory requirements, and potential side effects of long-term medication use. The limited understanding of Parkinson's etiology further complicates R&D efforts. Innovation areas like identifying biomarkers for early diagnosis, developing non-invasive treatment options, and improving drug efficacy and safety are ripe for exploration. Companies should invest in deep learning and AI technologies to accelerate drug discovery and patient-specific treatment plans. Despite these challenges, the market is inherently dynamic, driven by a persistent demand for improved therapies and a supportive regulatory environment encouraging breakthroughs. Strategic planning involves combining robust R&D initiatives with adaptive regulatory strategies to navigate complexities and ensure sustainable growth within this vital healthcare sector.

KEY MARKET STATISTICS
Base Year [2023] USD 6.67 billion
Estimated Year [2024] USD 7.21 billion
Forecast Year [2030] USD 11.64 billion
CAGR (%) 8.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Parkinson's Disease Therapeutics Market

The Parkinson's Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of Parkinson's disease among aging population
    • Development of new therapies and minimally invasive new devices
    • Strong drug pipeline under clinical research
  • Market Restraints
    • Availability of alternative treatments
  • Market Opportunities
    • Increasing pace of R&D by the government
    • Potential for pharmaceutical companies due to patent expiry
  • Market Challenges
    • Side effects of Parkinson's drugs

Porter's Five Forces: A Strategic Tool for Navigating the Parkinson's Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Parkinson's Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Parkinson's Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Parkinson's Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Parkinson's Disease Therapeutics Market

A detailed market share analysis in the Parkinson's Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Parkinson's Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Parkinson's Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Parkinson's Disease Therapeutics Market

A strategic analysis of the Parkinson's Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acadia Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, H. Lundbeck A/S, Mylan Inc. by Viatris Inc., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals Industries Ltd., UCB S.A., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Parkinson's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal.
  • Based on Drug Class, market is studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy.
  • Based on End Use, market is studied across Clinic and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of Parkinson's disease among aging population
      • 5.1.1.2. Development of new therapies and minimally invasive new devices
      • 5.1.1.3. Strong drug pipeline under clinical research
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing pace of R&D by the government
      • 5.1.3.2. Potential for pharmaceutical companies due to patent expiry
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of Parkinson's drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Parkinson's Disease Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Intestinal Infusion
  • 6.3. Oral
  • 6.4. Subcutaneous
  • 6.5. Transdermal

7. Parkinson's Disease Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anticholinergic
  • 7.3. Carbidopa/Levodopa
  • 7.4. COMT Inhibitor
  • 7.5. Dopamine Receptor Agonist
  • 7.6. MAO Inhibitor

8. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retailer Pharmacy

9. Parkinson's Disease Therapeutics Market, by End Use

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital

10. Americas Parkinson's Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Parkinson's Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Acadia Pharmaceuticals Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Apotex, Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cipla Limited
  • 8. DAIICHI SANKYO COMPANY, LIMITED
  • 9. H. Lundbeck A/S
  • 10. Mylan Inc. by Viatris Inc.
  • 11. Novartis AG
  • 12. Orion Corporation
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Teva Pharmaceuticals Industries Ltd.
  • 15. UCB S.A.
  • 16. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 193. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023